Hormonal and Bone Parameters in Pubertal Girls

V. CIRMANOVA1, I. ZOFKOVA1, P. Kasalicky2, V. Lanska3, M. Bayer4, L. Starka1, R. Kanceva1

1Institute of Endocrinology, Prague, Czech Republic, 2Affidea, Prague, Czech Republic, 3Institute of Clinical and Experimental Medicine, Prague, Czech Republic, 4Department of Children and Adolescents, Third Faculty of Medicine, Charles University, Hospital Královské Vinohrady, Prague, Czech Republic

Received June 26, 2017
Accepted July 16, 2017

Summary
Here we analyzed associations between muscles mass, total bone mineral content (BMC), lumbar spine bone density (BMD L1-L4) and serum or urine hormones in healthy peripubertal girls. Total BMC and areal BMD L1-L4, muscle mass and fat were measured by dual-energy X-ray absorptiometry (DXA). Muscle force (N) was estimated by a dynamometer. Circulating estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), 25-hydroxy vitamin D, parathyroid hormone (PTH), insulin-like growth factor 1 (IGF-1), leptin, osteocalcin, bone isoenzyme of alkaline phosphatase (bALP) and total calcium and phosphorus were quantified as the nocturnal melatonin and serotonin urinary excretion. Partial correlations adjusted for height, Tanner score and physical activity confirmed positive relationships between BMC or BMD L1-L4 (Z-score) and lean mass or fat. Furthermore, positive relationship was observed between BMC or BMD L1-L4 (Z-score) and serum leptin. After adjustment for Tanner score and physical activity, positive associations were observed between lean mass and IGF-1, leptin levels or muscle force. We proved positive relationships between bone mass and serum leptin in peripubertal girls.

Key words
Bone • Puberty • IGF-1 • Leptin • Serotonin • Melatonin

Introduction
It is known that the development and status of bones depends not only on the classical hormonal system regulating calcium phosphate metabolism (parathyroid hormone, calcitonin, vitamin D and its metabolites) but also on hormones with primary different effect as melatonin, serotonin, leptin and other adipokines.

Recently, there is a considerable interest generated about the interaction of melatonin and bone metabolism. Although, melatonin plays a key role in the circadian timing system, has a variety of biological actions such as regulation of seasonal reproductive function, immunity, antitumor and antioxidant effects, the osteogenic properties of the hormone still remain not fully elucidated (Park et al. 2011, Man et al. 2011, Satomura et al. 2007, Sethi et al. 2010). Accumulating evidence from in vitro and in vivo experiments using animal models has also suggested that melatonin may have an influence on skeletal growth, bone remodeling and to play a role in the parathyroid function. It has been reported that individuals with abnormalities in melatonin secretion, especially in the nocturnal phase, demonstrate considerable bone mass loss and also abnormalities of bone metabolism; the pivotal role of melatonin, estrogens and androgens on bone formation has also been underlined in these reports (Leder et al. 2003, Riggs et al. 2002, Manolagas et al. 2002). The early differentiation and higher expression of bone marker proteins and also the osteogenic differentiation on bone marrow stem cells are evoked by the presence of melatonin (Cardinali et al. 2003, Zaminy et al. 2008). Follicle stimulating hormone

https://doi.org/10.33549/physiolres.933733
modulation. This signaling pathway regulates the osteoprotegerin (RANKL/RANK/OPG system) interrelationship between vitamin D and muscle – bone osteoclasts and osteoblasts activity as well as mediates the effects of the hormones on the skeleton (Ostrowska 2009). The concept of muscle – bone unit assumes that bones and muscles represent evolutorial functional unit that is under the control of insulin-like growth factor I (IGF-1), gonadal hormones and vitamin D (Ashby et al. 2011, Fricke et al. 2010). The anabolic effect of IGF-1 on bone is well known and this is true during the puberty and adolescence (Mohan and Baylink 2005, Venken et al. 2005). The variation of IGF-1 expression is one of the causes of inter-individual differences of peak bone mass values (Karatay et al. 2007, Maimoun et al. 2010).

Vitamin D is a hormone which is involved in the regulation of bone development. It was reported that hypovitaminosis D, characterized by extremely low levels of 25-hydroxy vitamin D [25-(OH)D] decelerates muscle and bone development significantly more in girls than in boys, especially when associated with low physical activity (Ward et al. 2009). However, the interrelationship between vitamin D and muscle – bone unit in peripubertal girls has not been extensively studied.

Inconsistent data are available in the literature regarding the role of adipokines as well as serotonin – melatonin axis in bone development (Cirmanova et al. 2008). Leptin activates osteoblasts’ receptors and thus directly increases bone mass accrual. However, leptin also involves central inhibitory effect on the skeleton via β2 receptors that activate bone turnover (Hippmair et al. 2010).

Recently, research focused on the osteotropic effects of the neurotransmitter 5-hydroxytryptamin (serotonin). Dampening of serotonin production induced by Wnt/Lrp/beta-catenin circuit activation has an anabolic effect on bones (Yadav et al. 2010). In addition, some authors pointed out that higher serotonin tissue levels could explain the increased incidence of fractures in patients treated with antidepressants, inhibitors of the serotonin reuptake (Warden et al. 2010).

The exact role of melanotion on pubertal bone development is not elucidated. The indole inhibits production of gonadotropins (Srinivasan et al. 2009). On the other hand, it has direct bone anabolic effect which is mediated by specific receptors on the osteoblasts, inhibition of adipocytogenic differentiation and activation of osteogenesis (Radio et al. 2006, Sanchez-Hidalgo et al. 2007, Suzuki et al. 2008, Witt-Enderby et al. 2006, Zhang et al. 2010). To the best of the authors’ knowledge, the role of serotonin – melatonin system in the regulation of bone development has not been extensively investigated so far.

The aim of the study was to investigate the relationships between hormones, soft tissues and total bone mineral content (BMC) and lumbar spine bone mineral density (BMD L1-L4) in healthy peripubertal girls.

Methods

Subjects

A total of 100 healthy school girls randomly selected from several Prague regions were examined. The inclusion criteria for participation in the study were: age 9-15 (average 12.3±1.36) and Tanner stage 1-5 (average 2.3). Exclusion criteria were: malnutrition, milk intolerance, any known internal or psychiatric diseases or medicament treatment. Information about physical activity (normal school exercise once a week or recreation sports) and about dietary habits (intake of dairy products), neonatal data (fetal maturity and breastfeeding duration) were obtained by the use of a questionnaire from the parents of the participants. Informed consent was obtained from all the girls as well as their parents and the study was approved by the Ethics Committee of the Institute of Endocrinology in Prague.

Protocol

Blood samples on fasting were obtained to assess estradiol, FSH, LH, parathyroid hormone (PTH), 25(OH)D, IGF-1, leptin, osteocalcin, bone isoenzyme of alkaline phosphatase (bALP), total calcium and phosphorus. Nocturnal melatonin and serotonin urinary excretions were also studied. In all participants, values of total BMC (g), BMD L1-L4 (g/cm2 and its Z-score), lean-muscle and fat mass (g) were evaluated by use of dual-energy X-ray absorptiometry (DXA). Normal BMD in children is considered to be in the range of ±2 SD. The precision of the method is 1 %. Muscle force (N) was estimated by a dynamometer and was expressed as a sum
of isometric flexion and extension of fingers, arms, shanks and flexion and extension of the trunk.

**Laboratory parameters**

The measurement of estradiol was done by a commercial kit from the HUMA LAB, for FSH and LH HUMA LAB CS kits were also utilized (Krasna, Slovak Republic). 25(OH)D was measured using the RIA kit of IDS Company (The Boldons, UK). Serum PTH was set by the use of immunoassay (IBL International, Hamburg, Germany), similarly as urine serotonin excretion. Total blood calcium and phosphate were measured using absorption spectrophotometry (Cobas 6000, Manheim, Germany). Serum osteocalcin was determined by ECLIA method from Roche (Cobas 6000, Manheim, Germany) and bALP by IRMA kit from Beckman Coulter (Prague, Czech Republic).

**Statistics**

Mean, standard deviations, median, maximum and minimum were used for description of the investigated variables. To measure the dependence of two variables, while the subgroup of choose variables was held constant, the partial correlation coefficient was used. Normality was tested by Shapiro-Wilk’s W statistic. All “p” were two-sided and p<0.05 was regarded as significant. Statistical software SYSTAT was used for the calculations.

**Table 1.** Partial correlations of dependent variables (osteoalcin, bALP, total BMC, BMD L1-L4 and BMD Z-score) with independent variables (Ca – calcium, P – phosphate, serum and urine hormones, soft tissues and neonatal parameters) after removing linear effects of height, Tanner score and physical activity.

| Osteocalcin | bALP | BMC total | BMD L1-L4 | BMD Z-score |
|-------------|------|-----------|-----------|-------------|
| Ca          | 0.112| -0.061    | 0.022     | 0.004       | -0.018      |
| P           | 0.299**| -0.028   | -0.032    | -0.093      | -0.017      |
| 25(OH)D     | 0.252*| -0.098    | 0.015     | -0.001      | 0.028       |
| 1,25(OH)2D | 0.166| -0.062    | -0.044    | 0.132       | 0.014       |
| PTH         | 0.227*| 0.184     | -0.096    | -0.111      | -0.122      |
| IGF-1       | 0.174| -0.007    | 0.090     | 0.074       | 0.131       |
| Estradiol   | -0.037| -0.303*** | 0.142     | 0.143       | -0.096      |
| Leptin      | -0.214| 0.115     | 0.303*    | 0.217       | 0.275*      |
| Melatonin   | 0.313**| -0.122   | -0.138    | -0.130      | -0.242      |
| Serotonin   | 0.168| 0.234*    | -0.232    | -0.245      | -0.052      |
| Fat         | -0.385**| -0.039  | 0.564*** | 0.377**     | 0.482***    |
| Lean        | -0.100| -0.004    | 0.666*** | 0.188       | 0.551***    |
| Muscle force| -0.046| 0.001     | 0.349**   | 0.188       | 0.242       |
| Gestation   | 0.125| 0.120     | 0.196     | 0.194       | 0.190       |
| Breastfeeding| -0.029| -0.002   | 0.011     | -0.035      | -0.061      |

BMC – total bone mineral content, BMD – bone mineral density, PTH – parathyroid hormone, bALP – bone alkaline phosphatase isoenzyme, 25(OH)D – 25-hydroxy-vitamin D, IGF-1 – insulin-like growth factor 1, *p<0.05, **p<0.01, ***p<0.001.

**Results**

Table 1 indicates partial correlations between total BMC or BMD L1-L4 (g/cm² or Z-score) and independent variables after removing linear effects of height, Tanner and physical activity. Strong positive correlations were found between lean mass and BMC or BMD Z-score (p<0.001 and p<0.001, respectively), as well as between fat and BMC, BMD L1-L4 and BMD Z-score (p<0.001, p<0.01 and p<0.001). Positive association was observed between leptin and BMC or BMD Z-score (p<0.05 for both bone parameters). Positive relationship was noticed between serum phosphate, 25(OH)D, urine melatonin and serum.
ostecalcin (p<0.01, p<0.05 and p<0.05, respectively), similarly as between urine serotonin and bALP (p<0.05). However, none of these hormonal parameters correlated with BMC or BMD L1-L4.

Table 2. Partial correlations of dependent variables (lean and muscle strength) with independent variables (Ca – calcium, P – phosphate, serum and urine hormones) after removing effect of height, Tanner score and physical activity.

|          | Lean  | Muscle force |
|----------|-------|--------------|
| Ca       | -0.024| -0.013       |
| P        | 0.163 | -0.021       |
| 25(OH)D  | 0.009 | -0.212       |
| 1,25(OH)₂D₃ | 0.049 | -0.050       |
| PTH      | 0.118 | 0.034        |
| IGF1     | 0.363**| 0.261**      |
| Estradiol| 0.043 | -0.145       |
| Leptin   | 0.311* | 0.105       |
| Melatonin| -0.046| 0.039        |
| Serotonin| -0.067| -0.169       |

Abbreviations are the same as in Table 1.

Partial correlations between lean or muscle force and hormone indices after removing linear effects of height, Tanner and physical activity are depicted in Table 2, which shows positive associations between the lean or muscle strength and serum IGF-1 (p<0.01 and p<0.01, respectively) and between lean (but not muscle force) and serum leptin (p<0.05). No associations were found between neonatal parameters and BMC or BMD.

Discussion

The study confirmed positive association between pubertal bone and fat and leptin that was also reported by Rhie et al. (2010). Thus, both studies support the assumption that the direct stimulating effect of leptin on developing bone mass prevails over leptin inhibitory effect mediated through central mechanism (Hipmair et al. 2010).

In addition, a positive relationship was also found between leptin and lean mass values, which is in agreement with the data of Olmedillas et al. (2010) who found up-regulation of leptin receptors in hypertrophic biceps of professional tennis players. These results allow raising the hypothesis that the positive effect of leptin on bone is also muscle mediated.

It is acknowledged that muscle function is positively influenced by vitamin D. Ward et al. (2009) reported positive correlation between 25(OH)D levels and muscle strength in adolescent girls with a corresponding negative relationship between PTH levels and these parameters. In addition, positive correlations between 25(OH)D and lumbar spine BMD and trochanter BMC were outlined by El-Hajj Fuleihan et al. (2006). However, we were unable to prove any association between serum 25(OH)D or PTH and lean or bone mass. These findings could be in some extent explained by the differences in the study participants, i.e. the girls in the study of El-Hajj Fuleihan et al. (2006) were undernourished and the participants of the study of Ward et al. (2009) were younger than our ones.

It is well known that the female puberty is associated with an increase of gonadal steroid production. Osteotropic effect of estrogens is direct, but also mediated by the IGF-1 (Maimoun et al. 2010). In our study relationships between bone parameters and estradiol or IGF-1 levels were shown in unadjusted analysis. However, we were not able to prove these associations after eliminating the effects of age, Tanner score and physical activity. Since IGF-1 production and bone response to the hormone depend also on physical activity (Karatay et al. 2007, Maimoun et al. 2010) the lacking adjusted-association between serum IGF-1 levels and bone mass could be explained by relatively not pronounced physical activity in our girls. On the other hand, the effect of protein-caloric malnutrition could be eliminated in the vast majority of the girls of our study.

It is established that serotonin influences target tissues (including bones) in a bimodal way depending on the source of its synthesis (duodenum or central nervous system). Serotonin produced by enterochromafin cells inhibits bone formation, while serotonin produced in central nervous system has the opposite effect (Ducy and Karsenty 2010). The lack of association between serotonin levels and bone parameters in our girls could be explained by the different effects of the serotonin pools.

The assumption of the osteo-anabolic effects of melatonin is supported in the present study by proved positive association between nocturnal melatonin excretion and osteocalcin levels. This is in accordance with the recent findings that oral administration of melatonin can increase bone accrual during growth and...
can cure ovariectomy-induced structural and functional degeneration of bone by specifically increasing bone formation (Sharan et al. 2017). Future studies are needed to look more closely on the bone – melatonin relationship not only in peripubertal girls, but also boys and different age groups of female and male individuals.

Conflict of Interest
There is no conflict of interest.

Acknowledgements
Supported by MH CZ – DRO (Institute of Endocrinology – EU, 00023761) and by the by the MEYS CR (OP RDE, Excellent research – ENDO.CZ).

References
ASHBY RL, ADAMS JE, ROBERTS SA, MUGHAL MZ, WARD KA: The muscle-bone unit of peripheral and central skeletal sites in children and young adults. Osteoporos Int 22: 121-132, 2011.
CARDINALI DP, LADIZESKY MG, BOGGIO V, CUTRERA RA, MAUTALEN C: Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 34: 81-87, 2003.
CIRMANOVA V, BAYER M, STARKA L, ZAJICKOVA K: The effect of leptin on bone: an evolving concept of action. Physiol Res 57 (Suppl 1): S143-S151, 2008.
DUCY P, KARSENTY G: The two faces of serotonin in bone biology. J Cell Biol 191: 7-13, 2010.
EL-HAJJ FULEIHAN G, NABULSI M, TAMIM H, MAALOUF J, SALAMOUN M, KHALIFE H, CHOUCAIR M, ARABI A, VIETH R: Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 91: 405-412, 2006.
FRICKE O, BECCARD R, SEMLER O, SCHOENAU E: Analyses of muscular mass and function: the impact on bone mineral density and peak muscle mass. Pediatr Nephrol 25: 2393-2400, 2010.
HIPMAIR G, BOHLER N, MASCHEK W, SORIGUER F, ROJO-MARTINEZ G, SCHIMETTA W, PICHLER R: Serum leptin is correlated to high turnover in osteoporosis. Neuro Endocrinol Lett 31: 155-160, 2010.
KANCHEVA R, ZOKFOVA I, DUSILOVA-SULKOSKA S, KANCHEVA L, ROJDMARK S, PARIZEK A, DUSKOVA M, PALUCH Z, CIRMANOVA V, STARKA L: Hyperparathyroidism in hemodialyzed patients – relation to melatonin and reproductive hormones before and after parathyroidectomy. In: Hyperparathyroidism. SOTO GD, PUIG-DOMINGO M (eds), InTech Publishers, 2012, pp 67-96.
KARATAY S, YILDIRIM K, MELIKOGLU MA, AKCAY F, SENEL K: Effects of dynamic exercise on circulating IGF-1 and IGFBP-3 levels in patients with rheumatoid arthritis or ankylosing spondylitis. Clin Rheumatol 26: 1635-1639, 2007.
LEDER BZ, LEBLANC KM, SCHOENFELD DA, EASTELL R, FINKELSTEIN JS: Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88: 204-210, 2003.
MAIMOUN L, COSTE O, GALTIER F, MURA T, MARIANO-GOULART D, PARIS F, SULTAN C: Bone mineral density acquisition in peripubertal female rhythmic gymnasts is directly associated with plasma IGF1/IGF-binding protein 3 ratio. Eur J Endocrinol 163: 157-164, 2010.
MAN GC, WONG JH, WANG WW, SUN GQ, YEUNG BH, NG TB, LEE SK, NG BK, QIU Y, CHENG JC: Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis. J Pineal Res 50: 395-402, 2011.
MANOLAGAS SC, KOUSTENI S, JILKA RL: Sex steroids and bone. Recent Prog Horm Res 57: 385-409, 2002.
MOHAN S, BAYLINK DJ: Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-1 expression could contribute to peak bone mineral density differences. J Endocrinol 185: 415-420, 2005.
OLMEDILLAS H, SANCHIS-MOYSI J, FUENTES T, GUADALUPE-GRAU A, PONCE-GONZALEZ JG, MORALES-ALAMO D, SANTANA A, DORADO C, CALBET JA, GUERRA B: Muscle hypertrophy and increased expression of leptin receptors in the musculus triceps brachii of the dominant arm in professional tennis players. Eur J Appl Physiol 108: 749-758, 2010.
OSTROWSKA Z: Menopause, obesity, and bone status (in Polish). Postepy Hig Med Dosw (Online) 63: 39-46, 2009.
PARK KH, KANG JW, LEE EM, KIM JS, RHEE YH, KIM M, JEONG SJ, PARK YG, KIM SH: Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. *J Pineal Res* **51**: 187-194, 2011.

RADIO NM, DOCTOR JS, WITT-ENDERBY PA: Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. *J Pineal Res* **40**: 332-342, 2006.

RHIE YJ, LEE KH, CHUNG SC, KIM HS, KIM DH: Effects of body composition, leptin, and adiponectin on bone mineral density in prepubertal girls. *J Korean Med Sci* **25**: 1187-1190, 2010.

RIGGS BL, KHOSLA S, MELTON LJ 3RD: Sex steroids and the construction and conservation of the adult skeleton. *Endocr Rev* **23**: 279-302, 2002.

SANCHEZ-HIDALGO M, LU Z, TAN DX, MALDONADO MD, REITER RJ, GREGERMAN RI: Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: implications for osteoblast differentiation and osteoporosis. *Am J Physiol Regul Integr Comp Physiol* **292**: R2208-R2215, 2007.

SATOMURA K, TOBIUME S, TOKUYAMA R, YAMASAKI Y, KUDOH K, MAEDA E, NAGAYAMA M: Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. *J Pineal Res* **42**: 231-239, 2007.

SETHI S, RADIO NM, KOTLARCZYK MP, CHEN CT, WEI YH, JOCKERS R, WITT-ENDERBY PA: Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. *J Pineal Res* **49**: 222-238, 2010.

SHARAN K, LEWIS K, FURUKAWA T, YADAV VK: Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway. *J Pineal Res* **63**: doi:10.1111/jpi.12423, 2017.

SRINIVASAN V, SPENCE WD, PANDI-PERUMAL SR, BHATNAGAR KP, BRZEZINSKI A: Melatonin and human reproduction: shedding light on the darkness hormone. *Gynecol Endocrinol* **25**: 779-785, 2009.

SUZUKI N, SOMEI M, SEKI A, REITER RJ, HATTORI A: Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases. *J Pineal Res* **45**: 229-234, 2008.

VENKEN K, SCHUIT F, VAN LOMMEL L, TSUKAMOTO K, KOPCHICK JJ, COSCHIGANO K, OHLSSON C, MOVERARE S, BOonen S, BOUILLON R, VANDERSCHUEREN D: Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. *J Bone Miner Res* **20**: 2138-2149, 2005.

WARD KA, DAS G, BERRY JL, ROBERTS SA, RAWER R, ADAMS JE, MUGHAL Z: Vitamin D status and muscle function in post-menarchal adolescent girls. *J Clin Endocrinol Metab* **94**: 559-563, 2009.

WARDEN SJ, HASSETT SM, BOND JL, RYDBERG J, GROGG JD, HILLES EL, BOGENSCHUTZ ED, SMITH HD, FUCHS RK, BLIZIOOTES MM, TURNER CH: Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. *Bone* **46**: 985-992, 2010.

WITT-ENDERBY PA, RADIO NM, DOCTOR JS, DAVIS VL: Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. *J Pineal Res* **41**: 297-305, 2006.

YADAV VK, BALAJI S, SURESH PS, LIU XS, LU X, LI Z, GUO XE, MANN JI, BALAPURE AK, GERSHON MD, MEDHAMURTHY R, VIDAL M, KARSENTY G, DUCY P: Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. *Nat Med* **16**: 308-312, 2010.

ZAMINY A, RAGERDI KASHANI I, BARBARESTANI M, HEDAYATPOUR A, MAHMOUDI R, FARZANEH NEJAD A: Osteogenic differentiation of rat mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells: melatonin as a differentiation factor. *Iran Biomed J* **12**: 133-141, 2008.

ZHANG L, SU P, XU C, CHEN C, LIANG A, DU K, PENG Y, HUANG D: Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. *J Pineal Res* **49**: 364-372, 2010.